Literature DB >> 23286849

Best strategies for global HCV eradication.

Liesl M Hagan1, Raymond F Schinazi.   

Abstract

Worldwide eradication of hepatitis C virus (HCV) is possible through a combination of prevention education, universal clinical and targeted community screening, effective linkage to care and treatment with promising new direct-acting antiviral drug regimens. Universal screening should be offered in all healthcare visits, and parallel community screening efforts should prioritize high-prevalence, high-transmission populations including injection drug users, prison inmates and those with HIV/HCV co-infection. Increasing awareness of HCV infection through screening, improving treatment uptake and cure rates by providing linkage to care and more effective treatment, and ultimately combining education efforts with vaccination campaigns to prevent transmission and reinfection can slow and eventually stop the 'silent epidemic'.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23286849      PMCID: PMC4110680          DOI: 10.1111/liv.12063

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  96 in total

1.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

2.  A missed opportunity: hepatitis C screening of prisoners.

Authors:  Grace E Macalino; Darpun Dhawan; Josiah D Rich
Journal:  Am J Public Health       Date:  2005-10       Impact factor: 9.308

3.  Hepatitis C infection: eligibility for antiviral therapies.

Authors:  Jean Delwaide; Refaat El Saouda; Christiane Gérard; Jacques Belaïche
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-11       Impact factor: 2.566

4.  Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection.

Authors:  Glenn Wagner; Gery Ryan; Karen Chan Osilla; Laveeza Bhatti; Matthew Goetz; Mallory Witt
Journal:  AIDS Patient Care STDS       Date:  2009-09       Impact factor: 5.078

5.  Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission.

Authors:  Louise Kuhn; Grace M Aldrovandi; Moses Sinkala; Chipepo Kankasa; Mwiya Mwiya; Donald M Thea
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

Review 6.  [Sexual transmission of hepatitis C virus].

Authors:  Jade Ghosn; Marianne Leruez-Ville; Marie-Laure Chaix
Journal:  Presse Med       Date:  2005-08-27       Impact factor: 1.228

7.  The impact of the prevention programme of hepatitis C over more than a decade: the French experience.

Authors:  E Delarocque-Astagneau; C Meffre; F Dubois; C Pioche; Y Le Strat; F Roudot-Thoraval; P Hillon; C Silvain; D Dhumeaux; J-C Desenclos
Journal:  J Viral Hepat       Date:  2009-09-23       Impact factor: 3.728

8.  The disposition of hepatitis C antibody-positive patients in an urban hospital.

Authors:  B Putka; K Mullen; S Birdi; M Merheb
Journal:  J Viral Hepat       Date:  2009-11       Impact factor: 3.728

Review 9.  HCV drug discovery aimed at viral eradication.

Authors:  R F Schinazi; L Bassit; C Gavegnano
Journal:  J Viral Hepat       Date:  2009-12-18       Impact factor: 3.728

10.  Improving access to care by allowing self-referral to a hepatitis C clinic.

Authors:  K E Doucette; V Robson; S Shafran; D Kunimoto
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

View more
  40 in total

Review 1.  Extrahepatic immune related manifestations in chronic hepatitis C virus infection.

Authors:  Maria Tampaki; John Koskinas
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 2.  What's new in hepatitis C virus infections in children?

Authors:  Malgorzata Pawlowska; Krzysztof Domagalski; Anna Pniewska; Beata Smok; Waldemar Halota; Andrzej Tretyn
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China.

Authors:  Elizabeth Wu; Xisui Chen; Zhe Guan; Claudia Cao; Huiying Rao; Bo Feng; Melvin Chan; Sherry Fu; Andy Lin; Lai Wei; Anna S Lok
Journal:  Hepatol Int       Date:  2014-07-31       Impact factor: 6.047

4.  Pharmacokinetics of IDX184, a liver-targeted oral prodrug of 2'-methylguanosine-5'-monophosphate, in the monkey and formulation optimization for human exposure.

Authors:  Xin-Ru Pan-Zhou; Benjamin A Mayes; Hassan Rashidzadeh; Rahela Gasparac; Steven Smith; Sanjeev Bhadresa; Kusum Gupta; Marita Larsson Cohen; Charlie Bu; Steven S Good; Adel Moussa; Roger Rush
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-04-22       Impact factor: 2.441

5.  Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.

Authors:  Mary Caitlin Marshall; Jorge L Herrera
Journal:  Dig Dis Sci       Date:  2018-08-20       Impact factor: 3.199

Review 6.  Designing an HCV vaccine: a unique convergence of prevention and therapy?

Authors:  Christopher M Walker
Journal:  Curr Opin Virol       Date:  2017-05-25       Impact factor: 7.090

7.  The changing burden of hepatitis C virus infection in the United States: model-based predictions.

Authors:  Mina Kabiri; Alison B Jazwinski; Mark S Roberts; Andrew J Schaefer; Jagpreet Chhatwal
Journal:  Ann Intern Med       Date:  2014-08-05       Impact factor: 25.391

8.  Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America.

Authors:  Arturo Panduro; Sonia Roman
Journal:  World J Gastroenterol       Date:  2016-06-14       Impact factor: 5.742

Review 9.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

Review 10.  Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis.

Authors:  Josiah D Rich; Curt G Beckwith; Alexandria Macmadu; Brandon D L Marshall; Lauren Brinkley-Rubinstein; Joseph J Amon; M-J Milloy; Maximilian R F King; Jorge Sanchez; Lukoye Atwoli; Frederick L Altice
Journal:  Lancet       Date:  2016-07-14       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.